Jiuzhitang: Its affiliated company's new drug, Voradimab injection, has been approved for clinical trials
2026-11-19 16:26:05
According to CoinMeta, on November 19th, Jiuzhitang announced that its affiliated company, Beijing Kexin Meide Biomedical Technology Co., Ltd., in collaboration with its related company, US-based Ruimeiwei Biomedical Corporation, developed a class 1 innovative antibody drug called Voradumab injection, which targets the glucagon receptor. Recently, this drug has received the 'Drug Clinical Trial Approval Notice' issued by the National Medical Products Administration, allowing clinical trials to be conducted among patients with type 1 diabetes in China.
Source:Jin10 Data
This content is for market information only and does not constitute investment advice.
Follow CoinMeta official accounts to stay updated

Hot Articles
Refresh

What Is Bitmine? Why the Largest ETH Treasury Halted Buys
11-17 11:29

NVIDIA's stock tumbles 9% after the latest announcement; what impact will NVIDIA's decline have on the AI industry?
11-12 16:08

Is the Tangem wallet secure? No need to memorize a mnemonic phrase, can beginners use it with confidence?
11-12 17:31

SOL Currency's Latest Price Outlook: Can It Break Through the $90 Barrier?
11-11 11:59

Dow Jones 1,000-Point Swings: CPI Reversal or Bull Trap?
11-10 16:56



